Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%

Pharmaceuticals major Cipla on Tuesday reported a 35% year-on-year (YoY) decline in consolidated net profit to Rs 878 crore in Q2FY27, compared with Rs 1,351.17 crore in the corresponding quarter of the previous fiscal year.

Revenue from operations dropped 2.4% YoY to Rs 7,404 crore in Q2FY27, compared with Rs 7,589.44 crore in the year-ago period, according to the exchange filing submitted by the company.

Cipla posted a 26.7% YoY decline in earnings before interest, taxes, depreciation and amortization (EBITDA) to Rs 1,388 crore in Q2FY27, compared with Rs 1,894.75 crore in the year-ago period.


EBITDA margin contracted to 18.7% in the quarter from 25% in the corresponding period last fiscal year.

Cipla’s One India business, meanwhile, saw growth across its segments. The branded prescription business recorded market growth of 15%, with respiratory, urology, cardiac, anti-diabetes and dermatology therapies witnessing strong double-digit market growth.

The trade generics business delivered strong double-digit quarter-on-quarter (QoQ) growth, supported by portfolio expansion and the launch of more than 15 products during the quarter to address specific patient needs. In consumer health, brands such as Nicotex, Omnigel and Cipladine maintained their leadership positions in their respective market segments.

Cipla’s North America business reported quarterly revenue of $172 million, up $10 million from the previous quarter. Albuterol ranked No. 1 in the overall US Albuterol metered-dose inhaler (MDI) market, with a 22% market share.

The quarter also saw key regulatory and business developments in the US. The Food and Drug Administration (FDA) approved gAdvair Diskus, marking the first dry powder inhaler approval from Cipla’s US manufacturing network. The company also entered into an exclusive partnership with Qilu Pharmaceutical to commercialise a Keytruda biosimilar, strengthening its presence in oncology biosimilars.

In South Africa, Cipla’s secondary sales in the private market grew 6.5%, compared with overall market growth of 5%. Its prescription business maintained its No 2 position. The company's Emerging Markets and Europe (EMEU) business reported quarterly revenue of $101 million. Despite geopolitical uncertainties and market-specific headwinds, the business remained resilient, supported by strong execution and cost discipline across its direct-to-market (DTM) and business-to-business (B2B) segments.

Management Commentary

The pharmaceutical company said it remains focused on driving growth across its core businesses, improving productivity and strengthening its product pipeline.

“We expect North America performance to remain supported by our upcoming product pipeline. South Africa’s private market business continued to outperform the market, growing approximately 1.3 times faster. We remain focused on serving patients with trusted, high-quality medicines,” said Achin Gupta, MD and Global CEO of Cipla.

Cipla share price

Cipla shares came under pressure following the Q2 results announcement, falling 3% to hit an intraday low of Rs 1,320 on the NSE, against the previous close of Rs 1,355. The pharma stock continued to trade lower on Tuesday.

At around 1:48 PM, Cipla shares were trading at Rs 1,323.70, down 2.31% from the previous close on the NSE. So far in 2026, the stock has declined 12%, according to NSE data.